Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

Market Cap	8.82B +105.3%
Revenue (ttm)	970.32M -25.4%
Net Income	-272.78M
EPS	-0.51
Shares Out	538.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,015,880
Average Volume	29,233,895
Open	16.04
Previous Close	16.13
Day's Range	15.95 - 16.73
52-Week Range	6.64 - 22.63
Beta	0.59
RSI	56.70
Earnings Date	Apr 28, 2026

About SHE:300497

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers β-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,774
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300497

Financial Performance

In 2024, SHE:300497's revenue was 1.18 billion, a decrease of -26.83% compared to the previous year's 1.61 billion. Losses were -272.10 million, 35.5% more than in 2023.